US drug maker Moderna said it will request the Food and Drug Administration (FDA) to grant emergency use authorization for its Covid-19 vaccine to inoculate children under 6 years of age.
The company will submit the request to the FDA, as well as the European Medicines Agency and other global regulators "in the coming weeks", Xinhua news agency quoted Moderna as saying in a statement on Wednesday.
The submission was based on tests of its Covid-19 vaccine, known as mRNA-1273, in children aged 6 months to under 2 years, and 2 years to under 6 years.
The interim analysis showed a robust neutralising antibody response in both age groups after a 25 microgram two-dose primary series of mRNA-1273 along with a favourable safety profile, according to the company.
In the study, vaccine efficacy in children aged 6 months to 2 years was 43.7 per cent, and 37.5 per cent in the 2 to under 6 years age group, said Moderna.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU